Bausch Health and Salix in Collaboration With Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
Bausch Health and Salix in Collaboration With Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC.
魁北克拉瓦爾 / ACCESSWIRE / 2024年12月5日 / bausch health公司(紐交所:BHC)(tsx:BHC)及其胃腸病(GI)業務Salix藥品("Salix"),與美國疼痛基金會(USPF)、國際胃腸疾病基金會(IFFGD)和美國慢性疼痛協會(ACPA)聯合宣佈,今天,12月5日星期四,被定爲第二屆阿片類藥物引起的便秘(OIC)意識日。這個重要的日子旨在提高人們對阿片類藥物常被忽視的副作用的關注。通過提高認識和鼓勵開放對話,OIC意識日希望減輕圍繞該控件的污名,併爲受到OIC影響的許多患者提供支持。
"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."
「作爲一個致力於支持生活在疼痛控件中的個體的組織,我們自豪地參與今年的OIC意識日,」ACPA首席執行官凱西·薩普表示。「通過提高認識和改善醫療保健提供者、患者和護理人員之間的溝通,我們可以爲那些受此常見控件影響的人們帶來有意義的改變。」
In 2021, about 21% of adults in the U.S. experienced chronic pain. In 2019, 22% of adults with chronic pain were treated with a prescription opioid in the past three months. Opioids can cause OIC, which is a common side effect of opioid treatment. The annual recognition of OIC Awareness Day provides a platform for patients, caregivers, and healthcare providers to discuss this condition and encourage them to join the #OICAwarenessDay movement.
在2021年,約21%的美國成年人經歷了慢性疼痛。在2019年,22%的慢性疼痛成年人在過去三個月內接受了處方阿片類藥物的治療。阿片類藥物可能導致OIC,這是一種阿片類藥物治療的常見副作用。每年認識OIC意識日爲患者、護理人員和醫療保健提供者提供了一個討論該控件的平台,並鼓勵他們加入#OICAwarenessDay運動。
"We're deeply committed to bringing attention to those affected by OIC on this annual awareness day," said Ceciel Rooker, President and Executive Director of IFFGD. "Empowering patients to speak openly about their symptoms is crucial. It's the first step toward helping to ensure they receive the appropriate treatment, and not suffer in silence."
「我們深切致力於在這個年度意識日關注受到OIC影響的人們,」IFFGD主席兼執行董事塞西爾·魯克表示。「賦權患者公開談論他們的症狀至關重要。這是確保他們接受適當治療的第一步,而不是默默承受。」
In honor of the second annual OIC Awareness Day, Salix has refreshed the OICAwarenessDay.com website to offer valuable information and resources for healthcare providers, patients, and caregivers, addressing the causes, symptoms, and management of OIC. Additionally, Salix has partnered with influencers to spread the word online using the hashtag #vOICesOfOIC, launched a content program with Chronicon, a global community for people with chronic illnesses, and shared posts across their social media channels to increase awareness about OIC.
爲了紀念第二屆OIC意識日,Salix刷新了OICAwarenessDay.com網站,爲醫療保健提供者、患者和護理人員提供有關OIC的成因、症狀和管理的寶貴信息和資源。此外,Salix與影響者合作,在網上傳播信息,使用標籤#vOICesOfOIC,與Chronicon(一個全球慢性疾病患者社區)啓動內容計劃,並在其社交媒體渠道上分享帖子,以提高對OIC的認識。
"We're honored to be a part of OIC Awareness Day for the second year in a row," said Nicole Hemmenway, CEO of USPF. "By continuing to raise awareness about this condition, we aim to educate both healthcare providers and patients about OIC, a commonly overlooked side effect."
"我們很榮幸連續第二年參與OIC宣傳日,"美國疼痛基金會的首席執行官Nicole Hemmenway說道。"通過繼續提高大家對這種控件的認識,我們的目標是教育醫療保健提供者和患者了解OIC這一常被忽視的副作用。"
For more information on OIC and to learn how you can join the #OICAwarenessDay movement, please visit .
欲了解有關OIC的更多信息,以及如何加入#OICAwarenessDay運動,請訪問。
About Bausch Health
關於Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit and connect with us on LinkedIn.
Bausch Health公司(紐交所:BHC)(tsx:BHC)是一家全球多元化的製藥公司,通過我們不懈的努力交付更好的醫療保健成果,豐富生活。我們主要在胃腸病學、肝病學、神經病學、皮膚病學、國際藥品和眼部健康領域開發、生產和銷售一系列產品,通過我們對Bausch + Lomb公司的控股權。我們的目標是成爲一個在全球範圍內整合的醫療保健公司,受到患者、醫療保健從業者、員工和投資者的信任和重視。我們的胃腸病學業務Salix Pharmaceuticals是世界上最大的專業藥物企業之一,已經授權、開發並推出創新產品治療胃腸疾病超過30年。有關Salix的更多信息,請訪問 ,並在Twitter和LinkedIn上關注我們。有關Bausch Health的更多信息,請訪問 ,並在LinkedIn上關注我們。
About The U.S. Pain Foundation
關於美國疼痛基金會
The U.S. Pain Foundation is a 501(c)(3) nonprofit with a mission to empower, educate, connect, and advocate for individuals living with chronic illnesses and serious injuries that cause pain, as well as their care partners and clinicians. Through its multiple programs and services, the organization works to elevate the patient voice, increase disease-state education, improve pain care through policy change, expand outreach to underserved and marginalized communities, and provide comprehensive resources to ensure individuals are supported and empowered along their journeys. Learn more at uspainfoundation.org.
美國疼痛基金會是一個501(c)(3)非營利組織,使命是賦權、教育、連接並倡導生活在慢性疾病和嚴重傷害引起疼痛的人士及其護理夥伴和臨床醫生。通過其多個項目和服務,該組織旨在提高患者聲音,增加疾病狀態教育,通過政策變革改善疼痛護理,擴大對服務不足和邊緣化社區的宣傳,並提供全面資源,以確保個人在其旅程中得到支持和賦權。請訪問uspainfoundation.org了解更多信息。
About The International Foundation for Gastrointestinal Disorders
關於國際胃腸疾病基金會
The International Foundation for Gastrointestinal Disorders (IFFGD) is a nonprofit education and research organization dedicated to improving the lives of people affected by chronic gastrointestinal illnesses. Founded in 1991, IFFGD helps improve patient outcomes by enhancing awareness, improving education, and supporting and encouraging research into treatments and cures for chronic digestive disorders.
國際胃腸疾病基金會(IFFGD)是一個非營利教育和研究組織,致力於改善受慢性胃腸疾病影響的人的生活。IFFGD成立於1991年,通過提高意識、改善教育以及支持和鼓勵對慢性消化疾病的治療和治癒進行研究,來幫助改善患者的結果。
About The American Chronic Pain Association
關於美國慢性疼痛協會
The American Chronic Pain Association (ACPA) is a non-profit, 501(c) (3) organization. Our Mission is to facilitate peer support, education, hope, and motivation for individuals living with pain and those treating pain conditions. We strive to raise awareness among the health care community, policymakers, and the public at large about issues of living with physical and emotional pain. Our vision is to motivate those with pain conditions to seek quality care, to optimize healthcare office visits, and to prevent chronic disease.
美國慢性疼痛協會(ACPA)是一個非營利的501(c)(3)組織。我們的使命是爲那些生活在疼痛中的個人和治療疼痛的那些人提供同伴支持、教育、希望和動力。我們努力提高醫療保健社區、政策制定者和公衆在忍受身體和情感疼痛問題方面的意識。我們的願景是激勵那些有疼痛病症的人尋求高質量的護理,優化醫療辦公室的就診,預防慢性疾病。
Forward-looking Statements
前瞻性聲明
This news release may contain forward-looking statements about the future performance of Bausch Health which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
本新聞稿可能包含關於bausch health未來業績的前瞻性陳述,這些陳述通常可以通過使用「預計」、「希望」、「期望」、「打算」、「計劃」、「應該」、「可以」、「將」、「可能」、「相信」、「受制於」等詞及其變體或類似表達來識別。這些陳述基於管理層當前的期望和信念,並受到某些風險和不確定性的影響,這些因素可能導致實際結果與前瞻性陳述中描述的情況有實質性差異。實際結果受到與bausch health整體業務更廣泛相關的其他風險和不確定性的影響,包括在bausch health最近的10-k表格年報中更全面描述的因素,以及不時詳細列出的bausch health在美國證券交易委員會和加拿大證券管理局的其他文件中的因素,這些因素在此通過引用併入。
###
###
Investor Contact: |
Media Contact: |
|
Garen Sarafian |
Katie Savastano |
|
ir@bauschhealth.com |
corporate.communications@bauschhealth.com |
|
877-281-6642 (toll-free) |
(908) 569-3692 |
投資者聯繫人: |
媒體聯繫: |
|
加倫·薩拉菲安 |
Katie Savastano |
|
ir@bauschhealth.com |
corporate.communications@bauschhealth.com |
|
877-281-6642(免費電話) |
(908) 569-3692 |
SOURCE: Bausch Health Companies Inc.
來源:bausch health公司。
譯文內容由第三人軟體翻譯。